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2 Central picture 
2 Standardized cumulative mortality curves based on Cox regression comparing the 
absolute risks of death after surgery in patients with Perimount and Mitroflow aortic 
valves, respectively, standardized to the characteristics of all patients. 
3  
2.1 Central message 
Both Mitroflow and Perimount aortic valves demonstrate long term durability, but in 
comparison Perimount valves demonstrated significantly better overall survival. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Page 5 of 35 
 
3.1 Perspective Statement 
Both Mitroflow and Perimount aortic valve prosthesis demonstrated long term durability, 
however, Mitroflow valves were associated with an increased absolute risk of death.  Within 
the limitations of an observational study these results should influence valve choice and also 
stimulate increased attention during follow up of patients with Mitroflow valves. 
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3 Abstract 
3.1 Objectives 
Bioprosthetic aortic valves degenerate over time, and differences between brands could be 
expected. We compared two brands implanted in three different centers serving 3.3 million 
people.  
3.2 Methods 
Between 2000–2014 we identified 1,241 bioprosthetic aortic valve replacements using 
Mitroflow (Sorin, Milan, Italy) and 3,212 using Perimount (Edwards Lifesciences, Irvine, 
CA, USA) covering 88% of all aortic valve replacements in the region. Average differences 
in t-year mortality were derived from Cox regression. 
3.3 Results 
The complete case analyses included 881 Mitroflow replacements and 2,488 Perimount 
replacements. The median follow-up time and 25/75 percentiles was 5.0 years (3.3–7.2) and 
8.4 (5.1–10.6) years for Perimount and Mitroflow respectively. Multiple Cox regression 
analyses demonstrated significantly higher mortality with Mitroflow valves compared with 
Perimount (hazard ratio 1.27; 95% CI: 1.1-1.5; p<0.001). Average risk of death within five 
years was 25.0% with Mitroflow and 20.4% with Perimount.  Average difference in 5-year 
mortality based on Cox regression was 4.60% in favor of Perimount (95% CI: 1.02-8.02%; 
p=0.01) and the number needed to harm was 21.9 (95% CI: 12.7–80.5) within five years. 
Propensity matching confirmed two year survival differences 4.6% in favor of Perimount 
(95% CI: 1.2–7.9%; p=0.004), and further confirmed in a series of subgroups and a double 
robust analysis that takes into account both propensity for treatment and covariate relation to 
outcome.  
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3.4 Conclusions 
Mitroflow valves were associated with a significantly increased risk of death when compared 
to Perimount valves. 
3.5 Introduction 
Several studies have confirmed bioprosthetic aortic valve prostheses to be a viable alternative 
to mechanical valve prostheses, especially in the elderly.
1–4
 Several manufacturers have 
developed bioprosthetic valves with good long term performance when individually 
assessed.
5–7
 
Head-to-head comparison of the durability of bioprosthetic replacement valves have been 
difficult due to inconsistent reporting of results from surgery
4
 despite general consensus for 
evaluating and reporting the outcomes.
8,9
 However, criticism of Mitroflow replacement 
valves have risen due to early onset structural valve degeneration,
10–12
 and a recent study 
from one of the centers in the current study comparing Mitroflow valves to alternative 
Perimount valves supports this initial suspicion.
13
 
While the Mitroflow valve has a flat sewing ring, the sewing ring of the Perimount valve is 
scalloped, following the shape of the aortic annulus. The Perimount valves are made from 
three pieces of leaflet-material which are suspended in an external “scaffold”, and stitched to 
this, while the Mitroflow valve is made from one single piece of leaflet material, sutured at 
one of the three commissures, while the “scaffold” is internal (see supplementary Figure 1). 
The available results indicate that durability differences between biological valves may be an 
issue. Further knowledge of comparative valve durability is thus necessary for appropriate 
advise to patients.  To further investigate these findings and eliminate the possibility of 
inferior surgical results in a single center, an investigation of complete data from 
bioprosthetic aortic valve implantations from the entire western region of Denmark, covering 
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more than 3,3 million individuals, and more than 4,400 aortic valve replacements from three 
large centers for cardiac surgery were used.  
 
3.6 Methods 
In Denmark, all citizens are at birth assigned a unique and permanent civil registration 
number recorded in the Civil Registration System,
14
 and all health services (private and 
public), including pharmacy dispensations of prescribed drugs, are required by law to be 
recorded in several nationwide registries. Starting with a clinical database of all cardiac 
procedures in a population of 3.3 million individuals (The Western Denmark Heart Registry), 
we identified aortic valve replacements and joined the individuals using the civil registration 
number to several other government registries with information on causes of death, 
prescription medication and hospital admissions, to create a complete cohort of individuals 
with bioprosthetic aortic valves and medical history. Patient prosthetic mismatch was 
calculated from the patient body surface area and the chosen valves effective orifice area in 
vitro, and a ratio below 0.85 was considered a mismatch and included as a result. 
3.6.1 Study population 
The Western Denmark Heart Registry
15
  has since 2000 consistently been used to record data 
from all cardiac procedures performed at the three centers (Odense, Aarhus, Aalborg) that are 
part of this study. Guidelines for reporting valve replacements surgery can be found at this 
url: https://www.sts.org/sites/default/files/documents/pdf/guidelines/Akins.pdf We identified 
individuals who had undergone aortic valve replacement with either Mitroflow (Sorin, Milan, 
Italy) or Perimount (Edwards Lifesciences, Irvine, CA, USA) in the period between 2000 and 
2014. The Mitroflow valves used in the present study have prior to publication of the present 
study been withdrawn and substituted by a model with a different antimineralization 
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treatment. The National Register for Medicinal Products Statistics
17
 was used to identify 
medication before aortic valve replacement surgery. Medication information was extracted 30 
days before aortic valve replacement for all drugs except glucose lowering drugs for diabetes 
and drugs for hypertension were prescriptions 180 before surgery was included. The 
Anatomical Therapeutic Chemical Classification System codes (ATC) used are listed in 
Table 1. 
 
3.6.2 Statistical analysis 
3.6.2.1 Descriptive statistics 
Data for continuous data were presented as mean with standard deviation, categorical data as 
counts with percentages. The median potential follow-up time was estimated with the reverse 
Kaplan-Meier method in both treatment groups separately and reported with inter quartile 
ranges (IQR; 25% and 75% percentiles). 
3.6.2.2 Main analysis 
The primary outcome for all analyses was all cause absolute risk of death as a continuous 
time to event endpoint stopped five years after surgery or at date of administrative censoring 
(December 31, 2015).  The 5-year limit was chosen to justify positive probability of being 
uncensored across treatments, centers and confounder distribution.  The two-year survival 
status was evaluated as a binary endpoint and reported as difference in survival probability 
and number needed to harm one patient (one divided by difference in survival probability 
multiplied by 100). The reason for including two years was that there was no censoring prior 
to two years. A secondary endpoint was 30-day survival status.  
A multiple Cox regression model was used as out main model for the all-cause absolute risk 
of death, adjusting for all available covariates which include age at surgery groups (<60, 60-
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70, 70-80, >80), sex, hypertension, hyperlipidemia, smoking status (current, previous or 
never), diabetes, myocardial infarction, ejection fraction, creatinine (low, normal or high), 
bypass surgery, angina, body mass index, priority (acute or elective), endocarditis, ACE 
inhibitor, beta blocker, diuretic, calendar time (2000-2005, 2006-2008, 2009-2013) and valve 
size (<=21, 23, 25 or >= 27 mm). Information on the surgical center was not included 
because the positivity assumption was violated for center (zeros occurred in the treatment 
assignment probability, see supplementary Figure 2). Results were presented as hazard ratios 
with 95% confidence intervals and p-value for statistical significance. Based on the multiple 
Cox regression model we also obtained average treatment effects as differences between 
standardized absolute risk of death within 30 days, two years and five years after surgery and 
supplied with bootstrap confidence limits based on 200 bootstrap samples (G-formula, 
217
). 
Within the limitations of the observational nature of the data and the validity of the Cox 
regression model, the so-obtained average treatment effects are comparable to results of a 
hypothetical study which assigned the treatment group at random to all patients. 
3.6.2.3 Sensitivity analyses 
In addition, a series of sensitivity analyses was performed.  
The Cox model was performed in subsets of the data: all patients younger than 60 were 
excluded, an analysis where all valves of size <= 21 mm were excluded, a separate analysis 
in center Odense, and in the calendar period 2008–2013.  
A sensitivity analysis including only one center (Odense) was included, as well as an analysis 
replacing time period with surgical center included as a random variable. 
To account for potential misspecification of the multiple Cox regression model, a  propensity 
score matching analysis was performed.
18
 All propensity score analyses were performed 
using the complete cases only. Propensity scores were estimated with multiple logistic 
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regression adjusted for the same variables as included in the multiple Cox regression analysis, 
see supplementary Figure 3. For each patient we matched one patient of the respective other 
treatment arm. The match was determined as the patient who had the closest propensity score 
value in either direction.  The two-year survival status was used as outcome for the 
propensity score matching analysis and reported were differences in the two-year survival 
probabilities between Mitroflow and Perimount with 95% confidence limits hereby 
accounting for the uncertainty of the estimation of the propensity score model.
118
 The results 
are directly comparable with the two-year results of the main analysis, see Table 3.
119
  
A sensitivity analysis based on multiple imputation was performed using the Substantive 
Model Compatible Fully Conditional Specification algorithm.
22
 Multiple imputation results 
were reported as hazard ratios based on our main Cox regression analysis and 200 imputed 
datasets where Rubin’s rule was used to estimate the standard errors.  
Another sensitivity analysis was performed to check bias due to misspecification of the 
outcome model. We performed a double robust analysis which combines a model for 
outcome with inverse probability of treatment weighting. The probability of treatment was 
obtained with the propensity score model. The outcome model was another logistic 
regression model (same confounder adjustment as main model) for the two-year mortality 
risk and the main Cox regression model for the 5-year mortality risk. For the 5-year mortality 
risk we also needed a third model for the probability of censoring weights. The latter was 
obtained with a Cox regression model for the censoring times.  The doubly robust analysis is 
unbiased if either the treatment propensity score model or the outcome model is correctly 
specified.
 20
 
Data were managed using SAS 9.4 (Cary, NY, USA) for Windows, and statistical analysis 
with R statistics package (version 3.5) for Windows (R Core Team (2015))
23
. 
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3.6.3 Baseline characteristics 
Patient characteristics and characteristics of the matched population are presented in Table 1 
and a CONSORT diagram is presented in Figure 1. A total of 5,248 patients received a 
bioprosthetic aorta valve in one of the three participating centers during the years 2000–2013. 
Of these 167 were excluded from this study because of simultaneous mitral valve 
replacement. In 13 cases valve size was missing from the registry, and 615 patients that 
received other valve types than those compared were excluded. Thus 4,453 patients were 
included in the study cohort of which 1,241 received a Mitroflow valve, and 3,212 a 
Perimount valve. The number of reoperations was 22 for Perimount and 36 for Mitroflow, of 
which 11 versus 5 was due to infection (endocarditis), and 3 versus 31 due to structural valve 
degeneration, respectively. 
An overview of the number of valve replacements by thoracic center is presented in 
supplementary Figure 2. Only Mitroflow models 12A and LXA have been used. For 
Carpentier-Edwards Perimount valves type Magna 3000 and Magna Ease 3300 were used. 
None of the prosthesis used are coated with anti-calcification drugs. PPM information for 
Mitroflow and Perimount valves were available in 85% and 81% of the cases respectively, 
and the number of PPM for Mitroflow was 3 (<1%) out of 1,048 versus 337 (15%) out of 
2,255 for Perimount.  
3.2 Ethical considerations 
In Denmark, registry based studies do not require ethical committee approval. The Danish 
Data Protection Agency has approved the study (GEH-2014-015, I-Suite nr: 02733). 
3.7 Results 
The median follow-up time was 5.00 and 8.44 years for Perimount and Mitroflow 
respectively, and for this reason, all survival analyses were stopped at five years. During the 
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period 1.297 of individuals with Perimount valves died, and 890 with Mitroflow valves. 
Number of operations and deaths (%) by label (valve) size are included in Table 1 and Table 
2. Causes of death are presented in Table 2. The primary analysis, a Cox model revealed a 
significant difference in the absolute risk of death in favor of Perimount valves, see Figure 2, 
Figure 3 and Table 3 for overall analyses and analyses at 30 days, two years and five years. 
As surgical center was not in the main model because of violation of the positivity 
assumption, a subgroup analysis of Odense (Figure 4) was included as well as an analysis 
replacing time period with surgical center included as a random variable which both resulted 
in nearly identical result in favor of Perimount (p=0.002).  
3.7.1 Sensitivity analyses 
All sensitivity analysis unanimously demonstrated superiority in survival for Perimount 
valves. 
Figure 4 shows selected subgroups: After 2005 two out of three centers had a clear preference 
against Mitroflow valves, and only one center (Odense) continued without a clear preference. 
The figure shows the single center analysis of Odense after 2005. Also shown is an analysis 
where the smallest valve (21 mm) was excluded, only patients above 60 years of age and only 
the late part of the study period (2008–2013). 
In the propensity matched population the average two-year survival probability for Mitroflow 
patients compared to Perimount patients was 4.6% lower (95% CI: 1.2–7.9%; p=0.004) and 
the number needed to harm was 21.9 (95% CI: 12.7–80.5) within two years after operation.  
Analysis of imputated data using chained equations complete case missing and Cox model 
with death as endpoint were 1.19 for Mitroflow valves (95% CI: 1.03-1.38; p=0.02). 
Finally, a double robust analysis which uses inverse probability weighting of propensity 
scores and also adjusts for covariates influencing outcome was performed after five years. 
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This analysis revealed and average risk of death difference in favor of Perimount valve of 
7.13% (95% CI: 2.97-11.29). 
 
Discussion 
In this multi-center study of 4,453 bioprosthetic aortic valve replacements during 2000–2013 
with either Mitroflow or Perimount brand valves, we demonstrated good overall long term 
durability for both, but the direct comparison clearly identified a worse overall survival for 
Mitroflow valves (Figure 2). The findings were consistently demonstrated on three 
populations of either propensity matched individuals, the unaltered complete case population 
and complete cases with imputated missing data. The quality of the statistical methods 
applied was confirmed by several sensitivity analyses. 
These findings are in line Sénage et al,
12
 who also found durability problems for Mitroflow 
bioprosthetic valves compared to alternatives. Despite the comments by Pfeiffer and 
colleagues
24
 and the singular valve study by Piccardo et al
25
, we challenge the statement that 
this increase can be attributed to Mitroflow valves being selected for a specific subgroup of 
difficult cases (i.e. small aortic diameter with a resulting increased risk of patient-prosthesis 
mismatch), as exclusion of small valve diameters did not change the overall findings in this. 
Not surprisingly, our findings are in conformity with the single-center study by Nielsen et 
al,
13
 indicating that the increased risk observed in patients with Mitroflow valves are 
independent of the cardiac surgery center and concomitant medication, as data in that study 
was part of the current study. 
Several follow-up studies based on a singular bioprosthetic valves,
2,5,6
 including 
Mitroflow,
26–29
 from different institutions are available, but we believe that these findings 
cannot be used in a head-to-head comparison of aortic valves, which is in contrast with our 
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cohort which for the most part had selected valve manufacturer based on litigation rather than 
surgeons choice. Although admittedly local policies between the three centers participating, 
including treatment practice, patient selection and surgeon preferences may have influenced 
the choice of bioprosthetic valve used. We believe that the most part of these possible 
confounding factors are eliminated due to the geographical separation and independent 
management of each center. Our study therefore strongly suggest, that there are significant 
differences between valves, but cannot determine the cause. 
It is well known that bioprosthetic valves have limited durability due to degeneration is 
calcification of the biological material, leading to stiffness of the leaflets resulting in stenosis 
or break down creating incompetence.
30
 this calcification process is still not fully 
understood.
31
 Factors such as patient age, tissue fixation, mechanical stress have been shown 
to influence tissue mineralization, and treatment of the biological tissue with 
antimineralization agents have been shown to prolong durability.
32
 We are unable to 
challenge the possible benefits of antimineralization in our study, as none of the valves used 
during 2005–2015 included such coating. But to our knowledge no study has yet proven any 
increase in durability of valves with antimineralization agents, and consequently other studies 
are needed to assess this. 
Due to the seriousness of our findings we have speculated on the possible reasons of the 
observed increased risk of death for Mitroflow valves. Possibly Mitroflow valves deteriorate 
faster due to faster calcification, but we cannot know for sure without continuous 
echocardiographic data, which was not available in the observed cohort. Another theory is 
how the valves are constructed; Mitroflow valves are made up of a long strip bovine 
pericardium wedged around three sticks forming the valve commissures, and thus the strain 
of the mechanical movement of the valve opening and closing is tearing on the pericardium 
only. In Edwards valves the bovine pericardium flaps forming the valve is sewn onto the 
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three sticks forming the commissures, and thus the mechanical stress is absorbed by the 
sewing, which could be more durable than pericardium alone. Finally, the ratio of inner 
versus outer diameter of the valve differs among the two, which may also play a role. 
In summary, the compared valves differ in both materials, construction and 
geometry/hydrodynamic performance, which may all be factors contributing to faster 
structural valve deterioration, and increased workload on the left ventricle, eventually leading 
to increased risk of death. However, we are not able to give a causal explanation to the 
increased risk of death rate seen in the patients receiving Mitroflow valves, partly because 
this is a purely observational study, but also because we lack continuous echocardiographic 
data as well as autopsies of the people who have died, which could reveal important 
information on possible valve degeneration. 
Limitations 
The quality of epidemiological data available from the Danish Nationwide Registries may be 
debated to some minor extent, but the amount of scientific evidence gathered from these 
databases are very large indeed, and the majority of registries have been quality checked on 
several occasions. We therefore consider the overall quality of the Danish Registries to be 
very reliable, and not biased based towards one valve manufacturer. 
 The non-randomized nature of the data limits the conclusions to be valid only within the 
following assumptions of the statistical analyses. 
The validity of the propensity score matching method relies on the untestable assumption of 
no unmeasured confounders.
19
 The multiple imputation analysis relies on the assumption of 
missing at random. 
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Speculations on the reason for the observed increased risk of death in Mitroflow valves is 
limited by lack of echocardiographic data and possibly inaccurate and incomplete registration 
of the causes of death in both groups, as only a minor fractions of patients are autopsied. 
3.7.2 Implication 
This study clearly demonstrates inferiority of Mitroflow bioprosthetic aortic valves compared 
to Perimount. This should influence the surgeons selection between the two, in favor of the 
latter regardless of patient.  Consequently, we advice that all patients with a Mitroflow valve 
are closely followed to provide early detection of adverse events in relation to the prosthesis. 
The wider implication of the study is that further head-to-head comparisons of bioprosthetic 
valve durability are necessary. Ideally the findings should be confirmed in a randomized trial 
including valves with antimineralization treatment, but we generally believe the present 
findings strongly advise against implantation of Mitroflow valves, which may exclude that 
possibility due to ethical reasons. 
3.7.3 Conclusions 
Our findings consistently demonstrate that Mitroflow bioprosthetic aortic valves are 
associated with a significantly increased risk of death when compared to Perimount valves, 
from 30 days and at least up until five years following operation. 
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4 Sources of Funding 
The study received no external funding. 
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5 Figures 
Figure 1; CONSORT diagram. 
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Figure 2; Standardized cumulative mortality based on Cox regression analysis (absolute risk 
of death) curves comparing Carpentier-Edwards Perimount aortic valves to competitor Sorin 
Mitroflow including 95% confidence limits. The model was significant in favor of Perimount 
valves (p<0.001). The shaded areas are 95% confidence limits. 
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Figure 3; Complete case analysis of all-cause risk of death. Shown are hazard ratios from 
 multiple Cox regression analyses. 
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Figure 4; Standardized cumulative mortality based on Cox regression analysis (absolute risk 
of death) including 95% confidence limits comparing all-cause mortality of Sorin Mitroflow 
versus Carpentier-Edwards Perimount aortic valves in four subgroups of the population; age 
above 60, size above 21 mm, Odense surgical center and the period 2008–2013. These cuves 
uses the Cox model to simulate an experiment where each individual in each subgroup 
receives both treatments. The shaded areas are 95% confidence limits. 
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Figure 5; Video describing the study and results. 
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6 Tables 
Table 1. Patient characteristics of observed population and propensity matched population. 
Matching paired 881 Mitroflow replaments to 2,488 Perimount replacements both ways to 
obtain an analysis sample twice the original size. Center was not part of matching (see 
methods).  
 
Variable Levels Perimount Mitroflow 
Total count  3335 1293 
Included  3212 1241 
Complete cases  2488 881 
Follow up (days) mean (sd) 1358.6 (1098.5) 1880.0 (1257.8) 
Age (years) <60 104 (4.2) 4 (0.5) 
 60-70 689 (27.7) 149 (16.9) 
 70-80 1283 (51.6) 544 (61.7) 
 >80 412 (16.6) 184 (20.9) 
 missing 1 0 
Sex Female 875 (35.2) 420 (47.7) 
 Male 1613 (64.8) 461 (52.3) 
Hypertension No 935 (37.6) 421 (47.8) 
 Yes 1553 (62.4) 460 (52.2) 
Hyperlipidemia No 1052 (42.3) 482 (54.7) 
 Yes 1436 (57.7) 399 (45.3) 
Smoking Never 339 (13.6) 103 (11.7) 
 Prior 959 (38.5) 393 (44.6) 
 Current 1190 (47.8) 385 (43.7) 
Diabetes No 2039 (82.0) 742 (84.2) 
 Yes 449 (18.0) 139 (15.8) 
Myocardial infarction No 2214 (89.0) 775 (88.0) 
 Yes 274 (11.0) 106 (12.0) 
Ejection fraction (Units) mean (sd) 53.8 (11.3) 54.8 (10.9) 
 missing 370 172 
Creatinine <45 175 (7.0) 70 (7.9) 
 45-105 1969 (79.1) 654 (74.2) 
 >105 344 (13.8) 157 (17.8) 
 missing 484 291 
Bypass surgery No 1548 (62.2) 513 (58.2) 
 Yes 940 (37.8) 368 (41.8) 
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Center Aalborg 314 (9.4) 37 (2.9) 
 OUH 1120 (33.6) 813 (62.9) 
 Skejby 1901 (57.0) 443 (34.3) 
Angina No 1713 (68.9) 625 (70.9) 
 Stable 775 (31.1) 256 (29.1) 
Body Mass Index <22 290 (11.7) 118 (13.4) 
 22-26 608 (24.4) 243 (27.6) 
 26-30 1052 (42.3) 354 (40.2) 
 >30 538 (21.6) 166 (18.8) 
Priority Acute 61 (2.5) 17 (1.9) 
 Elective 2427 (97.5) 864 (98.1) 
Endocarditis No 2432 (97.7) 869 (98.6) 
 Yes 56 (2.3) 12 (1.4) 
ACE inhibitor (before) No 2121 (85.2) 787 (89.3) 
 Yes 367 (14.8) 94 (10.7) 
Beta blocker (before) No 1800 (72.3) 621 (70.5) 
 Yes 688 (27.7) 260 (29.5) 
Diuretic (before) No 2167 (87.1) 734 (83.3) 
 Yes 321 (12.9) 147 (16.7) 
Time period 2000-2005 49 (2.0) 206 (23.4) 
 2006-2008 509 (20.5) 341 (38.7) 
 2009-2013 1930 (77.6) 334 (37.9) 
Valve size <=21mm 667 (26.8) 327 (37.1) 
 23mm 282 (11.3) 67 (7.6) 
 25mm 870 (35.0) 237 (26.9) 
 >=27mm 669 (26.9) 250 (28.4) 
 
Table 2; Causes of death by aortic valve. The table shows the number of patients  who died 
at the end of follow-up according to the cause of death. The table does not account for 
differences in length of follow-up and should not be interpreted directly. 
Level Perimount (N=3212) Mitroflow (N=1241) Total (N=4453) 
Blood Pressure 41  31  72  
Cancer 167  89  256  
Cerebral vascular 
disease 
59  38  97  
Endocarditis 44  28  72  
Heart failure 62  56  118  
Infection 144  96  240  
Ischaemic heart 
disease 
189  129  318  
No information 
available  
1968  387  2355  
Other known causes of 235  143  378  
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death 
Other cardiovascular  303  244  547  
 
Table 3; Average treatment effect and difference from Cox model 
Time point Average risk of death % (95% CI) 
Mitroflow / Perimound 
Difference % (95% CI)  
30 days 5.0 (4.0-6.0) / 4.0 (3.2-4.6) 1.0 (0.21-1.86) p=0.014 
2 years 13.6 (9.8-11.7) / 11.0 (9.8-12.1) 2.7 (0.59-4.75) p=0.012 
5 years 25.0 (15.1-22) / 20.5 (18.7-22.2) 5.0 (1.02-8.02) p=0.011 
 
 
